Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000929638-25-004298
Filing Date
2025-11-14
Accepted
2025-11-14 16:10:50
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8154
  Complete submission text file 0000929638-25-004298.txt   10186
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Subject) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-58467 | Film No.: 251486189
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022
Business Address 444 MADISON AVENUE 41ST FLOOR NEW YORK NY 10022 646-701-7428
Lind Global Fund II LP (Filed by) CIK: 0001871665 (see all company filings)

EIN.: 863914253 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A